These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 18974395)

  • 41. MEK inhibitors against MET-amplified non-small cell lung cancer.
    Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
    Egile C; Kenigsberg M; Delaisi C; Bégassat F; Do-Vale V; Mestadier J; Bonche F; Bénard T; Nicolas JP; Valence S; Lefranc C; Francesconi E; Castell C; Lefebvre AM; Nemecek C; Calvet L; Goulaouic H
    Mol Cancer Ther; 2015 Feb; 14(2):384-94. PubMed ID: 25504634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
    McDermott U; Pusapati RV; Christensen JG; Gray NS; Settleman J
    Cancer Res; 2010 Feb; 70(4):1625-34. PubMed ID: 20124471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
    Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
    BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
    Funakoshi Y; Mukohara T; Tomioka H; Ekyalongo RC; Kataoka Y; Inui Y; Kawamori Y; Toyoda M; Kiyota N; Fujiwara Y; Minami H
    Invest New Drugs; 2013 Oct; 31(5):1158-68. PubMed ID: 23568717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
    Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
    Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Chen C; Chang YC; Lan MS; Breslin M
    Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
    Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
    Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
    Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.